BBOT
BridgeBio Oncology Therapeutics Inc.·Healthcare
8.40
5.138%(−0.46)
Market ClosedLast Updated: — ET
52W L: $8.0852W H: $14.87
BBOT NEWS
globenewswire.com
Mar 18
BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced multiple presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 being held on April 17-22, 2026, in San Diego, California. The abstracts released today can be found on the AACR website here.
globenewswire.com
Mar 6
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor
BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over HRAS and NRAS, and displays strong activity in KRAS mutant preclinical models, including KRASG12D and KRASG12V
globenewswire.com
Mar 5
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway. Announced encouraging preliminary safety and efficacy data across all three programs: BBO-8520's differentiated efficacy and safety profile as monotherapy and at active doses in combination with pembrolizumab with a potentially differentiated liver toxicity profile, BBO-11818 producing the first publicly disclosed partial response in PDAC as a panKRAS inhibitor, and BBO-10203 showing no hyperglycemia without HbA1c restriction — establishing the clinical foundation for differentiated combination strategies, including BBOT's internal KRAS plus PI3Kα breaker program.
globenewswire.com
Feb 12
BBOT to Participate in Upcoming Investor Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in the upcoming months.
globenewswire.com
Feb 11
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on February 10, 2026 under BBOT's 2025 Inducement Plan as a material inducement to the employment of two individuals hired by BBOT in January 2026.
247wallst.com
Feb 11
Here Are Wednesday’s Top Wall Street Analyst Research Calls: BP Plc., Cloudflare, Dick’s Sporting Goods, Mattel, Noble Corp., Qualcomm, Tyler Technologies, XPO, and More
Pre-Market Stock Futures: Futures are trading higher after a stellar and surprising January jobs report as we get to the middle of the trading week. While the Dow Jones Industrial Average managed a winning day, closing up 0.20% at 50,188, the disappointment over the December retail sales report hung over the market like a sword... Here Are Wednesday's Top Wall Street Analyst Research Calls: BP Plc., Cloudflare, Dick's Sporting Goods, Mattel, Noble Corp., Qualcomm, Tyler Technologies, XPO, and More.
